Faster Drug Discovery

TREAT-AD’s mission is to address the urgent need for therapies to effectively treat or prevent Alzheimer’s disease

The National Institute on Aging (NIA), part of the National Institutes of Health (NIH), funded two complementary TREAT-AD research centers with the goal of diversifying and reinvigorating the AD drug development pipeline. The centers are focused on developing high-quality research tools and technologies to validate and advance the next generation of drug targets for Alzheimer’s disease (AD). Data, methods, and computational and experimental tools will be disseminated openly and free-of-charge to the broader research community—including academia and industry—for use in drug discovery and in research to better understand the complex biology of AD.